<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39376806</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of a Single Fixed Dose of 3 mg Rasburicase for the Prevention and Management of Hyperuricemia in Tumor Lysis Syndrome in Adults With Cancer.</ArticleTitle><Pagination><StartPage>e68664</StartPage><MedlinePgn>e68664</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e68664</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.68664</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tumor lysis syndrome (TLS) is a critical and potentially fatal complication linked to specific types of cancer. Rasburicase stands as a crucial medication necessary for the prevention and treatment of hyperuricemia, a condition commonly associated with TLS. Due to a shortage of rasburicase during the COVID-19 pandemic, a fixed-dose strategy of 3 mg rasburicase was used in many adult cancer patients in our center.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The objective of this study was to assess the effectiveness of a fixed dose of 3 mg rasburicase in preventing and managing hyperuricemia associated with TLS in adult cancer patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS"> We conducted a retrospective, observational cohort study between March 2020 and February 2022. The study included adult patients who received a fixed dose of 3 mg rasburicase. The primary outcome measure was the reduction in serum uric acid (UA) levels at 24 and 48 hours after treatment, with the aim of achieving and maintaining normal UA levels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS"> Seventeen patients in the treatment group and 20 patients in the prevention group were included. In the treatment group, 15 (88%) patients had normalization of serum UA, which is considered to be &lt;7 mg/dL (median: 4.48 mg/dL) at 24 hours, and 16 (94%) patients had achieved normal UA at 48 hours (median: 2.78 mg/dL) after receiving the rasburicase dose. In the prevention group, all 20 (100%) patients achieved normal UA at 24 hours after receiving the rasburicase dose.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on these findings, a single fixed dose of 3 mg rasburicase is effective for preventing and managing hyperuricemia associated with TLS in high-risk patients.</AbstractText><CopyrightInformation>Copyright © 2024, Bakhsh et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bakhsh</LastName><ForeName>Sabirin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Mansoor Ahmed</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshamrani</LastName><ForeName>Majed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Affairs, Johnson &amp;amp; Johnson Innovative Medicine, Riyadh, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mufti</LastName><ForeName>Roula</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Oncology, King Faisal Specialist Hospital and Research Centre, Jeddah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naeem</LastName><ForeName>Anjum</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlMansour</LastName><ForeName>Mubarak</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsaeed</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Adult Hematology/Bone Marrow Transplantation (BMT), Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alahmari</LastName><ForeName>Mousa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aseeri</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, SAU.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">3 mg single fixed dose</Keyword><Keyword MajorTopicYN="N">cost-effectiveness</Keyword><Keyword MajorTopicYN="N">hematology and oncology</Keyword><Keyword MajorTopicYN="N">rasburicase</Keyword><Keyword MajorTopicYN="N">tumor lysis syndrome</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39376806</ArticleId><ArticleId IdType="pmc">PMC11456990</ArticleId><ArticleId IdType="doi">10.7759/cureus.68664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The tumor lysis syndrome. Howard SC, Jones DP, Pui CH. N Engl J Med. 2011;364:1844–1854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437249</ArticleId><ArticleId IdType="pubmed">21561350</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride A, Trifilio S, Baxter N, Gregory TK, Howard SC. J Adv Pract Oncol. 8(7) Orlando (FL): Elsevier Churchill Livingstone; 2017. Managing tumor lysis syndrome in the era of novel cancer therapies; pp. 705–720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188097</ArticleId><ArticleId IdType="pubmed">30333933</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumour lysis syndrome: new therapeutic strategies and classification. Cairo MS, Bishop M. Br J Haematol. 2004;127:3–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15384972</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Abu-Alfa AK, Younes A. http://10.1053/j.ajkd.2009.10.056 Am J Kidney Dis. 2010;55:0–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20420966</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Alakel N, Middeke JM, Schetelig J. OncoTargets Ther. 2017;10:597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5295804</ArticleId><ArticleId IdType="pubmed">28203093</ArticleId></ArticleIdList></Reference><Reference><Citation>Elitek (Rasburicase) for Injection for Intravenous Use [Prescribing Information]. Bridgewater, NJ: Sanofi-Aventis. 2017. https://products.sanofi.us/elitek/elitek.html https://products.sanofi.us/elitek/elitek.html</Citation></Reference><Reference><Citation>Kent and Medway Cancer Collaborative Guidelines at NHS for use of RASBURICASE in Adult Haematology and Oncology Patients July 2022.  [
Jul;
2024 
]. https://www.kmcc.nhs.uk/s3/assets/files/guidelines-for-use-of-rasburicase-v7.pdf https://www.kmcc.nhs.uk/s3/assets/files/guidelines-for-use-of-rasburicase-v7.pdf</Citation></Reference><Reference><Citation>Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Cairo MS, Coiffier B, Reiter A, Younes A. Br J Haematol. 2010;149:578–586.</Citation><ArticleIdList><ArticleId IdType="pubmed">20331465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lexi-Comp [Version 1.5.0 (112)] Hudson (OH): Lexi-Comp, Inc; [ Jul; 2024 ]. 2022. Elitek (rasburicase) prescribing information. Bridgewater, NJ: Sanofi-Aventis US LLC.</Citation></Reference><Reference><Citation> European Medicines Agency (EMA) summary of product characteristics for Fasturtec (rasburicase)  [
Jul;
2024 
]. https://www.ema.europa.eu/en/documents/product-information/fasturtec-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product-information/fasturtec-epar-product-information_en.pdf</Citation></Reference><Reference><Citation>Effectiveness of a single 6-mg fixed dose of rasburicase for prevention or management of hyperuricemia associated with tumor lysis syndrome in adults with cancer. KhanMA KhanMA, Alshamrani MA, Aseeri MA. https://jhoponline.com/issue-archive/2019-issues/jhop-march-2019-vol-9-no-1/17700:effectiveness-of-a-single-6-mg-fixed-dose-of-rasburicase-for-prevention-or-management-of-hyperuricemia-associated-with-tumor-lysis-syndrome-in-adults-with-cancer J Hematol Oncol Pharm. 2019;9:30.</Citation></Reference><Reference><Citation>The efficacy and cost-impact of rasburicase 3 mg versus 6 mg for the management of tumor lysis syndrome: a multicenter analysis. Marjoncu D, Holman K. J Oncol Pharm Pract. 2023;29:893–898.</Citation><ArticleIdList><ArticleId IdType="pubmed">35306913</ArticleId></ArticleIdList></Reference><Reference><Citation>Superiority of rasburicase versus allopurinol on serum uric acid control in adult patients with hematological malignancies at risk of developing tumor lysis syndrome: results of a randomized comparative phase III study. Cortes J, Seiter K, Maziarz RT, et al.  https://ashpublications.org/blood/article/112/11/919/74979/Superiority-of-Rasburicase-Versus-Allopurinol-on. Blood. 2008;112:919.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. Sonbol MB, Yadav H, Vaidya R, et al. Am J Hematol. 2013;88:152–154.</Citation><ArticleIdList><ArticleId IdType="pubmed">22573495</ArticleId></ArticleIdList></Reference><Reference><Citation>PRNewswire. FDA approved Elitek (rasburicase) for management of plasma uric acid levels in adults with leukemia, lymphoma, solid tumors receiving anti-cancer therapy. https://www.news.sanofi.us/press-releases?item=118501 https://www.news.sanofi.us/press-releases?item=118501</Citation></Reference><Reference><Citation>Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. J Clin Oncol. 2008;26:2767–2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509186</ArticleId></ArticleIdList></Reference><Reference><Citation>Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Coutsouvelis J, Wiseman M, Hui L, et al. Br J Clin Pharmacol. 2013;75:550–553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3579269</ArticleId><ArticleId IdType="pubmed">22686734</ArticleId></ArticleIdList></Reference><Reference><Citation>The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis. Yu X, Liu L, Nie X, Li J, Zhang J, Zhao L, Wang X. https://doi.org/10.1111/jcpt.12479. J Clin Pharm Ther. 2017;42:18–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">27888526</ArticleId></ArticleIdList></Reference><Reference><Citation>Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Trifilio SM, Pi J, Zook J, et al. Bone Marrow Transplant. 2011;46:800–805.</Citation><ArticleIdList><ArticleId IdType="pubmed">20818444</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>